LNSR Overview

LENSAR, Inc. is a commercial-stage medical device company focused on designing, developing, and marketing advanced systems for the treatment of cataracts and the management of astigmatism as an integral aspect of the procedure. The Company's product portfolio includes the LENSAR Laser System and the ALLY Robotic Cataract Laser System and their associated consumable components. It has developed its ALLY System as a compact, highly ergonomic system utilizing an extremely fast dual-modality laser and integrating artificial intelligence into proprietary imaging and software. ALLY is designed to transform cataract surgery by utilizing its advanced robotic technologies with the ability to perform the entire procedure in a sterile operating room or in-office surgical suite. ALLY allows the surgeon to switch between cataract laser and the surgeon’s existing phacoemulsification device without moving patients from room-to-room. ALLY includes its proprietary Streamline software technology.

Wall Street analysts forecast LNSR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LNSR is15.00 USD with a low forecast of 15.00 USD and a high forecast of 15.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

LENSAR Inc revenue for the last quarter amounts to 13.43M USD, decreased -5.16

LENSAR Inc. EPS for the last quarter amounts to 2.36 USD, decreased -201.72

LENSAR Inc (LNSR) has 150 emplpoyees as of May 30 2026.

Today LNSR has the market capitalization of 70.21M USD.